Two melanoma treatments approved for PBS listing
24 December 2019
In a boost for melanoma patients across Australia, the Federal Government’s PBAC has recommended subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients. Two melanoma treatments are recommended by the PBAC for PBS listing - nivolumab for resected Stage III/IV (high risk) metastatic melanoma, and the combination ipilimumab and nivolumab as first-line therapy for Stage IV (advanced) melanoma.
Co-Medical Directors of Melanoma Institute Australia, Professor Georgina Long and Professor Richard Scolyer, said providing subsidised access to these treatments was wonderful news for melanoma patients and their families around Australia, as until now, they could only access these treatments through clinical trials or on compassionate grounds, or face costs of tens of thousands of dollars.
‘Our clinical trials have proven nivolumab is effective in preventing melanoma recurrence and its spread to other organs including the brain, lungs and liver in the majority of high risk resected Stage III patients,’ said Professor Georgina Long. ‘Our trials have also proven the effectiveness of the combination immunotherapy as front line treatment for Stage IV melanoma patients where their disease has already spread to other organs, including the brain.’
‘Providing certainty of access to these treatments via the PBS will be life-changing and life-saving, and we applaud the Federal Government for this decision,’ added Professor Richard Scolyer.
Shown in photo: Melanoma Institute Australia's Co-Medical Directors - Professor Georgina Long and Professor Richard Scolyer
A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.
It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Georgina Long hands on baton of SMR Presidency
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
City2Surf 2020
Join in the fun of the virtual event, and together we can run over melanoma!
Top melanoma experts at MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Top melanoma experts from MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Melanoma Supportive Care Needs research study.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Research reveals long-term benefit of adjuvant therapy for Stage III melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
New online melanoma risk calculators critical to saving lives
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
Professor Richard Scolyer receives University of Sydney Alumni Award.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
Uniting together despite the distance
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
Important Update: Masks required at Poche Centre
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.